AR 301

Drug Profile

AR 301

Alternative Names: AR 301 (anti-Sa mAb) - Aridis Pharmaceuticals; AR-301 - Aridis Pharmaceuticals; KBSA-301; Salvecin

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kenta Biotech
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pneumonia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sepsis; Staphylococcal infections
  • Phase I/II Pneumonia

Most Recent Events

  • 05 Jun 2017 Efficacy and adverse events data from a phase I/IIa trial in Pneumonia and Staphylococcal infections released by Aridis Pharmaceuticals
  • 22 Apr 2017 Adverse events data from a phase I/II trial in Pneumonia and Staphylococcal infections presented at the at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 01 Sep 2016 Aridis completes a phase I/IIa clinical trial for Pneumonia and Staphylococcal infections (Adjunctive treatment) in USA, United Kingdom, Belgium, France and Spain (NCT01589185)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top